@shipam.bsky.social
Reposted
Just out! We challenge the prevailing caution and advocate for a biomarker-guided approach soon to be tested in the STRATIFY lupus trial: Rituximab–belimumab combination for refractory SLE @shipam.bsky.social @versusarthritis.bsky.social www.thelancet.com/journals/lan...
Revisiting safety and refining benefit of rituximab–belimumab combination for refractory SLE
B-cell depletion using rituximab is used to treat systemic lupus erythematosus (SLE),
particularly for patients whose disease is refractory to conventional immunosuppressants
(eg, mycophenolate), and ...
www.thelancet.com
October 17, 2025 at 10:24 AM
Just out! We challenge the prevailing caution and advocate for a biomarker-guided approach soon to be tested in the STRATIFY lupus trial: Rituximab–belimumab combination for refractory SLE @shipam.bsky.social @versusarthritis.bsky.social www.thelancet.com/journals/lan...
@arrdept-ucldom.bsky.social
Just out! Our latest lupus paper shows IgA2⁺ B-cells & IgA2-anti-dsDNA Abs are selectively targeted
doi.org/10.1016/j.xc...
Builds on theranostic discovery doi.org/10.1016/S266...
On BEAT-Lupus doi.org/10.7326/M21-...
Lupus ≠ one-size-fits-all doi.org/10.1084/jem....
Just out! Our latest lupus paper shows IgA2⁺ B-cells & IgA2-anti-dsDNA Abs are selectively targeted
doi.org/10.1016/j.xc...
Builds on theranostic discovery doi.org/10.1016/S266...
On BEAT-Lupus doi.org/10.7326/M21-...
Lupus ≠ one-size-fits-all doi.org/10.1084/jem....
July 23, 2025 at 5:52 PM
@arrdept-ucldom.bsky.social
Just out! Our latest lupus paper shows IgA2⁺ B-cells & IgA2-anti-dsDNA Abs are selectively targeted
doi.org/10.1016/j.xc...
Builds on theranostic discovery doi.org/10.1016/S266...
On BEAT-Lupus doi.org/10.7326/M21-...
Lupus ≠ one-size-fits-all doi.org/10.1084/jem....
Just out! Our latest lupus paper shows IgA2⁺ B-cells & IgA2-anti-dsDNA Abs are selectively targeted
doi.org/10.1016/j.xc...
Builds on theranostic discovery doi.org/10.1016/S266...
On BEAT-Lupus doi.org/10.7326/M21-...
Lupus ≠ one-size-fits-all doi.org/10.1084/jem....
Reposted
STRATIFY lupus is a newly funded precision medicine biomarker enrichment trial funded by @versusarthritis.bsky.social and @nihr.bsky.social with support from @glaxosmithkline.bsky.social in collaboration with @shipam.bsky.social & many UK lupus specialist centres. Will start recruitment early 2026.
March 28, 2025 at 9:17 AM
STRATIFY lupus is a newly funded precision medicine biomarker enrichment trial funded by @versusarthritis.bsky.social and @nihr.bsky.social with support from @glaxosmithkline.bsky.social in collaboration with @shipam.bsky.social & many UK lupus specialist centres. Will start recruitment early 2026.